Biogen Partners with TJ Biopharma to Expand Felzartamab in Greater China
Biogen has entered into a strategic agreement with TJ Biopharma to transfer the rights of Felzartamab for the Greater China region. This partnership aims to enhance the development and commercialization of this promising therapeutic asset.